Evolutec Ltd Release: Phase II Post-Cataract Eye Inflammation Trial Is Fully Recruited
Evolutec (AIM: EVC), the biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and autoimmune diseases, announces that its proof of concept Phase II trial with its lead compound, rEV131, against inflammation following cataract surgery is fully recruited.